

**IN THE UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF TEXAS
MARSHALL DIVISION**

ALLERGAN, INC.,

Plaintiff,

v.

TEVA PHARMACEUTICALS USA, INC.,
AKORN, INC., MYLAN PHARMACEUTICALS
INC., MYLAN INC., and INNOPHARMA

Defendants.

Civil Action No. 2:15-cv-1455-WCB

(Consolidated) LEAD CASE

DEFENDANT AKORN'S UNOPPOSED MOTION FOR TAXATION OF COSTS

Defendant Akorn, Inc. ("Akorn") hereby moves for an order directing the Clerk of the Court to tax costs against Plaintiffs Allergan, Inc. ("Allergan") and The Saint Regis Mohawk Tribe (collectively "Plaintiffs") in the amount of \$41,458.86, as indicated in the attached bill of costs.

In compliance with Local Rule CV-54(b), Counsel for Akorn and Allergan met and conferred on November 8, 2017, in an effort to submit to the court an agreed bill of costs. On November 13, 2017, counsel for Allergan indicated it has no objections to the attached proposed bill of costs.

Accordingly, Akorn respectfully requests that the Court direct the Clerk to tax costs against Plaintiffs in the amount of \$41,458.86.

November 13, 2017

Respectfully submitted,

/s/ E. Glenn Thames, Jr.

Michael R. Dzwonczyk
Azadeh Kokabi
SUGHRUE MION PLLC
2100 Pennsylvania Ave NW, Suite 800
Washington, DC 20037
Tel: 202-293-7060
Fax: 202-293-7860
mdzwonczyk@sughrue.com
akokabi@sughrue.com

E. Glenn Thames, Jr.
POTTER MINTON
A PROFESSIONAL CORPORATION
110 N College Avenue, Suite 500
Tyler, TX 75702
Tel: 903-597-8311
Fax: 903-593-0846
glennthames@potterminton.com

**COUNSEL FOR DEFENDANT
AKORN, INC.**

CERTIFICATE OF SERVICE

I hereby certify that all counsel of record who have consented to electronic service and are being served with a copy of this document via the Court's CM/ECF system per Local Rule CV- 5(a)(3) on November 13, 2017.

/s/ E. Glenn Thames, Jr.

E. Glenn Thames, Jr.

CERTIFICATE OF COMPLIANCE

In compliance with Local Rule CV-54(b), I hereby certify that on November 8, 2017, Azy Kokabi on behalf of Akorn, Inc. ("Akorn") met and conferred with Susan Morrison on behalf of Plaintiff Allergan, Inc. ("Allergan"). Counsel for Allergan indicated it does not object to Akorn's proposed bill of costs.

/s/Azy S. Kokabi

Azy S. Kokabi